Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon Progression

Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon Progression Jonathan D. Schwartz, Max Sung, Myron Schwartz, Deborah Lehrer, John Mandeli, Leonard Liebes, Alec Goldenberg, Matthew Volm Oncologist 2005; 10: 718-727 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in hepatobiliary cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify the etiologic factors contributing to the increasing incidence of hepatocellular carcinoma in the U.S. Explain the rationale for antiangiogenic therapeutic strategies in the treatment of hepatocellular carcinoma. Describe the clinical features associated with a particularly poor prognosis in unresectable hepatocellular carcinoma. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 25, 2005 Most Recent Review: Oct. 25, 2005* Most Recent Update: Oct. 25, 2005 Date Credit Expires: Oct. 25, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.